Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Qiagen N.V. (QGEN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 6,548,790
  • Shares Outstanding, K 234,090
  • Annual Sales, $ 1,281 M
  • Annual Income, $ 127 M
  • 36-Month Beta 1.13
  • Price/Sales 5.11
  • Price/Book 2.40

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.20 +4.16%
on 11/03/16
28.50 -4.25%
on 11/10/16
+3.35 (+13.99%)
since 11/02/16
3-Month
23.94 +13.99%
on 11/02/16
28.50 -4.25%
on 11/10/16
+0.66 (+2.48%)
since 09/02/16
52-Week
19.94 +36.86%
on 06/27/16
28.50 -4.25%
on 11/10/16
+0.88 (+3.33%)
since 12/02/15

Most Recent Stories

More News
Mass Spectrometry Adopted by Clinical Laboratories Around the World

Mass spectrometry (MS) is a highly selective analytic technique which provides significantly more accurate measurements and as a result, is now being used in an increasing number of clinical laboratories....

QIAGEN GeneReader NGS System to Relaunch in U.S. Market

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the validation of new and improved sequencing chemistry for its GeneReader NGS System, the world's first complete Sample to Insight...

QIAGEN's GeneReader NGS System Streamlines Data Management for Labs

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with lab informatics company Genohm to empower GeneReader NGS System users with seamless data management by integrating...

World Protein Purification and Isolation Market Report 2016 - Opportunities and Forecasts 2014-2022 - Research and Markets

Research and Markets has announced the addition of the "World Protein Purification and Isolation Market - Opportunities and Forecasts, 2014 - 2022" report to their offering. The global ...

Upgrade Alert for QIAGEN (QGEN)

QIAGEN (NASDAQ:QGEN) was upgraded from Underperform to Neutral at BofA/Merrill today. The stock closed yesterday at $26.27 on volume of 3.1 million shares, above average daily volume of 854,000. QIAGEN...

Qiagen (QGEN) Tops Q3 Earnings & Sales, Provides '17 View

Qiagen NV (QGEN) reported third-quarter 2016 adjusted earnings per share (EPS) of 29 cents, beating both the Zacks Consensus Estimate and the year-ago adjusted number by 7.7%.

QIAGEN Reports Results for Third Quarter and First Nine Months of 2016

-- QIAGEN records strong third quarter with accelerating 2016 performance:

Drug Stocks to Watch for Earnings on Nov 2; AGN, ZTS & More

Five more companies from the healthcare sector are set to report their third-quarter results on Nov 2. Let's see how things are shaping up for their respective announcements.

5 Healthcare Stocks Poised to Trump Q3 Earnings

Medical is one of the many sectors that is witnessing earnings and revenue growth this quarter.

QIAGEN Shareholders Approve Return of Approximately $250 million in Cash to Shareholders via Synthetic Share Repurchase

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved a proposal to return approximately $250 million in cash to shareholders through a synthetic...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.

See More

Support & Resistance

2nd Resistance Point 27.83
1st Resistance Point 27.56
Last Price 27.29
1st Support Level 27.06
2nd Support Level 26.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.